share_log

EF Hutton Maintains Buy on Marinus Pharma, Lowers Price Target to $3

Benzinga ·  Oct 24 21:48  · Ratings

EF Hutton analyst Jason Kolbert maintains Marinus Pharma (NASDAQ:MRNS) with a Buy and lowers the price target from $23 to $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment